Company Profile
Dong-A Socio provides the pharmaceutical business in South Korea. Its business is organized into Holding Company. Its portfolio also includes Over-the-Counter Drugs and Quai-Drugs, Biosimilars and Consignment Medicines, Logistics, Packaging Solutions, and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder.
Its portfolio also includes DMB-3115, a biosimilar of Stelara in Phase 3 clinical trial, DA-1241 in Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis, DA-1726 in Phase 1 clinical trial to treat obesity, and STP0404 for the treatment of AIDS medical devices and equipment.
Its portfolio also includes healthcare solutions to customers in Bacchus, over-the-counter, consumer healthcare, and cosmetics, health functional food, contract development and manufacturing organization for biosimilar and pharmaceutical products, and oligonucleotide therapeutics, functional sports drinks under the POCARI SWEAT brand, logistics and fulfillment services, glass bottles, PET bottles, aluminum and plastic caps, and paper packaging boxes, mineral and carbonated water, and mixed drinks, and IT and construction services.
Additionally, it is involved in engineering. Its portfolio also includes cargo, courier, and automobile transport arrangement, transportation warehousing and leasing, real estate development, agricultural product distribution, management consulting, business management, and architectural, electric work, fire protection, and housing contracting services. Founded in 1932, Dong-A Socio is headquartered in Seoul, South Korea.